ArticleJournal of clinical microbiology2011
Rapid diagnosis of extensively drug-resistant tuberculosis by use of a reverse line blot hybridization assay.
Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Article
- Cathelicidins and defensins antimicrobial host defense peptides in the treatment of TB and HIV: Pharmacogenomic and nanomedicine approaches towards improved therapeutic outcomes.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Comparison of Multiplex Real-Time PCR and PCR-Reverse Blot Hybridization Assays for the Direct and Rapid Detection of Porcine Circovirus Type 2 Genotypes.Frontiers in veterinary science · 2020Article
- Multiplex detection of extensively drug resistant tuberculosis using binary deoxyribozyme sensors.Biosensors & bioelectronics · 2017Article
- Development of a Rapid Reverse Blot Hybridization Assay for Detection of Clinically Relevant Antibiotic Resistance Genes in Blood Cultures Testing Positive for Gram-Negative Bacteria.Frontiers in microbiology · 2017Article
- Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use.Journal of clinical microbiology · 2017Article
- Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.Tuberculosis (Edinburgh, Scotland) · 2015Article
- Article
- Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing.Journal of clinical microbiology · 2015Article
- Emerging technologies for monitoring drug-resistant tuberculosis at the point-of-care.Advanced drug delivery reviews · 2014Review
- Rifoligotyping assay: an alternative method for rapid detection of rifampicin resistance inBiotechnology, biotechnological equipment · 2014Article
- Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis.Journal of clinical microbiology · 2013Article
- Article
- Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient.Pharmaceuticals (Basel, Switzerland) · 2012Article
- Rapid detection of rpoB gene mutations conferring rifampin resistance in Mycobacterium tuberculosis.Journal of clinical microbiology · 2012Article
- Article
- Clonal population of Mycobacterium tuberculosis strains reside within multiple lung cavities.PloS one · 2011Article
- Utility of Line Probe Assay for the Early Detection of Multidrug-Resistant Pulmonary Tuberculosis.Journal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance in tuberculosis (TB) is a matter of grave concern for TB control programs, as there is currently no cure for some extensively drug-resistant (XDR) strains. There is concern that this resistance could transmit, stressing the need for additional control measures, rapid diagnostic methods, and newer drugs for treatment. We developed an in-house assay that can rapidly detect resistance to drugs involved in the definition of XDR-TB directly from smear-positive specimens. Two hundred fifteen phenotypically XDR-TB isolates and 50 pansusceptible isolates were analyzed using a reverse line blot hybridization (RLBH) assay. The assay was also successfully applied to 73 smear-positive clinical specimens. The RLBH assay exhibited good sensitivity for the detection of resistance to isoniazid (99%), rifampin (99%), fluoroquinolones (95.3%), and second-line aminoglycosides (94.8%). The results from application of this assay on direct smear-positive clinical specimens revealed 93% concordance with the phenotypic drug susceptibility test (DST) results for the above-mentioned drugs. The time to accurate DST results was significantly reduced from weeks to 3 days. This molecular assay is a highly accurate tool for screening for XDR-TB, which achieves a substantial reduction in diagnostic delays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.